Bellevue Group Ag Intra Cellular Therapies, Inc. Transaction History

Bellevue Group Ag

  • $5.93 Billion
  • Q3 2024

A detailed history of Bellevue Group Ag transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Bellevue Group Ag holds 2,485,627 shares of ITCI stock, worth $207 Million. This represents 3.06% of its overall portfolio holdings.

Number of Shares
2,485,627
Previous 2,471,285 0.58%
Holding current value
$207 Million
Previous $169 Million 7.38%
% of portfolio
3.06%
Previous 2.83%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$67.99 - $80.84 $975,112 - $1.16 Million
14,342 Added 0.58%
2,485,627 $182 Million
Q2 2024

Aug 14, 2024
SELL
$64.76 - $79.84 $22.5 Million - $27.8 Million
-348,197 Reduced 12.35%
2,471,285 $169 Million
Q1 2024

May 15, 2024
SELL
$64.37 - $75.65 $15.9 Million - $18.7 Million
-246,918 Reduced 8.05%
2,819,482 $195 Million
Q4 2023

Feb 14, 2024
SELL
$46.37 - $73.65 $4.82 Million - $7.65 Million
-103,850 Reduced 3.28%
3,066,400 $220 Million
Q3 2023

Nov 14, 2023
SELL
$52.09 - $64.1 $1.64 Million - $2.02 Million
-31,550 Reduced 0.99%
3,170,250 $165 Million
Q2 2023

Aug 14, 2023
SELL
$54.67 - $66.44 $3.62 Million - $4.4 Million
-66,200 Reduced 2.03%
3,201,800 $203 Million
Q1 2023

May 15, 2023
SELL
$43.8 - $56.99 $3.25 Million - $4.23 Million
-74,236 Reduced 2.22%
3,268,000 $177 Million
Q4 2022

Feb 14, 2023
BUY
$44.07 - $54.45 $571,014 - $705,508
12,957 Added 0.39%
3,342,236 $177 Million
Q3 2022

Nov 14, 2022
SELL
$42.7 - $59.99 $858,270 - $1.21 Million
-20,100 Reduced 0.6%
3,329,279 $155 Million
Q2 2022

Aug 11, 2022
SELL
$43.0 - $65.64 $3.45 Million - $5.27 Million
-80,240 Reduced 2.34%
3,349,379 $191 Million
Q1 2022

May 13, 2022
SELL
$38.74 - $62.09 $7.72 Million - $12.4 Million
-199,300 Reduced 5.49%
3,429,619 $210 Million
Q4 2021

Feb 10, 2022
SELL
$35.2 - $53.42 $5.1 Million - $7.75 Million
-145,000 Reduced 3.84%
3,628,919 $190 Million
Q3 2021

Nov 12, 2021
BUY
$28.72 - $42.49 $4.71 Million - $6.97 Million
164,000 Added 4.54%
3,773,919 $141 Million
Q2 2021

Aug 12, 2021
SELL
$29.3 - $44.5 $1.47 Million - $2.23 Million
-50,000 Reduced 1.37%
3,609,919 $147 Million
Q4 2020

Feb 16, 2021
BUY
$23.34 - $32.22 $1.87 Million - $2.58 Million
80,000 Added 2.23%
3,659,919 $116 Million
Q3 2020

Nov 16, 2020
SELL
$17.61 - $31.86 $3.52 Million - $6.37 Million
-200,000 Reduced 5.29%
3,579,919 $91.9 Million
Q2 2020

Aug 13, 2020
BUY
$14.35 - $26.64 $690,235 - $1.28 Million
48,100 Added 1.29%
3,779,919 $97 Million
Q1 2020

May 14, 2020
BUY
$12.31 - $33.12 $16.8 Million - $45.2 Million
1,365,819 Added 57.73%
3,731,819 $57.4 Million
Q4 2019

Feb 14, 2020
SELL
$7.26 - $38.49 $1.62 Million - $8.58 Million
-222,990 Reduced 8.61%
2,366,000 $81.2 Million
Q3 2019

Nov 14, 2019
BUY
$7.47 - $14.03 $2.57 Million - $4.82 Million
343,490 Added 15.3%
2,588,990 $19.3 Million
Q2 2019

Aug 14, 2019
BUY
$10.65 - $14.29 $23.9 Million - $32.1 Million
2,245,500 New
2,245,500 $29.1 Million
Q1 2019

May 15, 2019
SELL
$10.9 - $14.09 $573,340 - $741,134
-52,600 Closed
0 $0
Q4 2018

Feb 12, 2019
SELL
$10.36 - $20.96 $20,720 - $41,920
-2,000 Reduced 3.66%
52,600 $599,000
Q3 2018

Nov 13, 2018
SELL
$17.77 - $22.9 $449,581 - $579,370
-25,300 Reduced 31.66%
54,600 $1.19 Million
Q2 2018

Aug 07, 2018
SELL
$17.33 - $23.4 $192,362 - $259,739
-11,100 Reduced 12.2%
79,900 $1.41 Million
Q1 2018

May 09, 2018
SELL
$15.16 - $25.49 $22,740 - $38,235
-1,500 Reduced 1.62%
91,000 $1.92 Million
Q4 2017

Feb 14, 2018
BUY
$14.27 - $16.79 $749,175 - $881,475
52,500 Added 131.25%
92,500 $1.34 Million
Q2 2017

Aug 14, 2017
BUY
N/A
40,000
40,000 $497,000

Others Institutions Holding ITCI

# of Institutions
377
Shares Held
84.1M
Call Options Held
319K
Put Options Held
143K
View Full List

About Intra-Cellular Therapies, Inc.

ITCI Quotes by TradingView
  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $7.88B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track This Portfolio

Track Bellevue Group Ag Portfolio

Follow Bellevue Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email